The Influence of Socioeconomic Status and Diet on Multiple Sclerosis Outcomes: Sarah Levy, PhD
March 11th 2025The assistant professor in the department of neurology at Mount Sinai talked about a recent study that highlighted how socioeconomic status and diet could significantly impact physical and cognitive outcomes in patients with MS. [WATCH TIME: 2 minutes]
Treatment Decisions and Personalization for Pediatric MOGAD: Kelsey Poisson, MD
March 7th 2025The child neurologist and neuroimmunologist at Nationwide Children’s Hospital provided clinical insight on the complexities of treating pediatric MOGAD, including treatment options, decision-making factors, and emerging therapies. [WATCH TIME: 4 minutes]
Pilavapadin Heads for Phase 3 Trial Following Positive PROGRESS Study of Neuropathic Pain
March 6th 2025Based on the results of PROGRESS and the previous RELIEF-DPN-1 study, the 10 mg dose of pilavapadin was selected to move forward in clinical development for diabetic peripheral neuropathic pain.
Furthering the Conversation of Treatment Personalization in NMOSD: Tammy Smith, MD, PhD
March 6th 2025The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed advancing personalized medicine for patients with neuromyelitis optica spectrum disorder, a rare disorder of the central nervous system. [WATCH TIME: 4 minutes]
DMD Community Eyes First Cell Therapy Approval Following FDA’s Acceptance of Deramiocel Submission
March 4th 2025With a scheduled PDUFA date of August 31, 2025, deramiocel looks to become the first marketed treatment for cardiomyopathy in DMD, one of the leading causes of death in this patient population.
FDA Approves Expanded Use of Eculizumab for Pediatric Myasthenia Gravis
March 4th 2025Originally approved in 2007, eculizumab (Soliris; Alexion/AstraZeneca) is now available to treat both adult and pediatric patients with generalized myasthenia gravis, becoming the first available option for younger patients with the disease.